CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study

Original Research2020 Jul 18.

JOURNAL:ESC Heart Fail. Article Link

Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT-HF study

JA Borovac, D Glavas, ZS Grabovac et al. Keywords: acute decompensated heart failure; catestatin; HF; hospital mortality; risk stratification; soluble suppression of tumourigenicity

Full Text PDF